Building On Bayer
Executive Summary
Onyx has learned a lot in its almost twenty year history with Bayer, managing through the upside and downside of having a Big Pharma partner.
You may also be interested in...
Deals Of The Week Wonders: Who Will Buy Onyx?
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.
Bayer/Onyx Nexavar Extends Life In Rare Thyroid Cancer
Regulatory filings will be based on results of the Phase III DECISION trial reported at ASCO showing a near double progression-free survival advantage compared to placebo; no further overall survival analyses will be done because of crossover.